MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2024.02.008

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2024

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.

Zhang Xiaoshuai, Xu Na, Yang Yunfan, Lin Hai, Liu Bingcheng, Du Xin, Liu Xiaoli, Liang Rong, Chen Chunyan, Huang Jian, Zhu Huanling, Pan Ling, Wang Xiaodong, Li Guohui, Liu Zhuogang, Zhang Yanqing, Liu Zhenfang, Hu Jianda, Liu Chunshui, Li Fei, Yang Wei, Meng Li, Han Yanqiu, Lin Li'e, Zhao Zhenyu, Tu Chuanqing, Zheng Caifeng, Bai Yanliang, Zhou Zeping, Chen Suning, Qiu Huiying, Yang Lijie, Sun Xiuli, Sun Hui, Zhou Li, Liu Zelin, Wang Danyu, Guo Jianxin, Pang Liping, Zeng Qingshu, Suo Xiaohui, Zhang Weihua, Zheng Yuanjun, Zhang Yanli, Li Weiming, Jiang Qian

СтатьяМногоцентровое исследованиеСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting.

PATIENTS AND

METHODS

Data from patients with chronic-phase CML receiving initial a second-generation tyrosine-kinase inhibitor (2G-TKI, nilotinib, dasatinib or flumatinib) or imatinib therapy from 77 Chinese centers were retrospectively interrogated. Propensity-score matching (PSM) analyses were performed to to compare therapy responses and outcomes among these 4 TKIs.

RESULTS

2,496 patients receiving initial nilotinib (n = 512), dasatinib (n = 134), flumatinib (n = 411) or imatinib (n = 1,439) therapy were retrospectively interrogated in this study. PSM analyses indicated that patients receiving initial nilotinib, dasatinib or flumatinib therapy had comparable cytogenetic and molecular responses (p = .28-.91) and survival outcomes including failure-free survival (FFS, p = .28-.43), progression-free survival (PFS, p = .19-.93) and overall survival (OS) (p values = .76-.78) but had significantly higher cumulative incidences of cytogenetic and molecular responses (all p values < .001) and higher probabilities of FFS (p < .001-.01) than those receiving imatinib therapy, despite comparable PFS (p = .18-.89) and OS (p = .23-.30).

CONCLUSION

Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.

Для цитирования: Zhang Xiaoshuai, Xu Na, Yang Yunfan, Lin Hai, Liu Bingcheng, Du Xin, Liu Xiaoli, Liang Rong, Chen Chunyan, Huang Jian, Zhu Huanling, Pan Ling, Wang Xiaodong, Li Guohui, Liu Zhuogang, Zhang Yanqing, Liu Zhenfang, Hu Jianda, Liu Chunshui, Li Fei, Yang Wei, Meng Li, Han Yanqiu, Lin Li'e, Zhao Zhenyu, Tu Chuanqing, Zheng Caifeng, Bai Yanliang, Zhou Zeping, Chen Suning, Qiu Huiying, Yang Lijie, Sun Xiuli, Sun Hui, Zhou Li, Liu Zelin, Wang Danyu, Guo Jianxin, Pang Liping, Zeng Qingshu, Suo Xiaohui, Zhang Weihua, Zheng Yuanjun, Zhang Yanli, Li Weiming, Jiang Qian. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.. Clinical lymphoma, myeloma & leukemia. 2024. DOI: 10.1016/j.clml.2024.02.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.